Chronic inflammation in end-stage renal disease and dialysis

被引:280
作者
Cobo, Gabriela [1 ]
Lindholm, Bengt [2 ,3 ]
Stenvinkel, Peter [2 ,3 ]
机构
[1] Hosp Eugenio Espejo, Dept Educ & Res, Quito, Ecuador
[2] Karolinska Inst, Div Renal Med, Stockholm, Sweden
[3] Karolinska Inst, Baxter Novum, Stockholm, Sweden
关键词
chronic inflammation; end stage renal disease; expanded hemodialyisis; middle molecules; CHRONIC KIDNEY-DISEASE; C-REACTIVE PROTEIN; HEMODIALYSIS-PATIENTS; UREMIC TOXINS; DOUBLE-BLIND; SERUM; MORTALITY; ASSOCIATION; INHIBITION; THERAPY;
D O I
10.1093/ndt/gfy175
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Under normal conditions, inflammation is a protective and physiological response to various harmful stimuli. However, in several chronic debilitating disorders, such as chronic kidney disease, inflammation becomes maladaptive, uncontrolled and persistent. Systemic persistent inflammation has, for almost 20 years, been recognized as a major contributor to the uraemic phenotype (such as cardiovascular disease, protein energy wasting, depression, osteoporosis and frailty), and a predictor of cardiovascular and total mortality. Since inflammation is mechanistically related to several ageing processes (inflammageing), it may be a major driver of a progeric phenotype in the uraemic milieu. Inflammation is likely the consequence of a multifactorial aetiology and interacts with a number of factors that emerge when uraemic toxins accumulate. Beside interventions aiming to decrease the production of inflammatory molecules in the uraemic milieu, novel strategies to increase the removal of large middle molecules, such as expanded haemodialysis, may be an opportunity to decrease the inflammatory allostatic load associated with retention of middle molecular weight uraemic toxins.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 55 条
  • [1] The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease
    Alves, Filipa Caeiro
    Sun, Jia
    Qureshi, Abdul Rashid
    Dai, Lu
    Snaedal, Sunna
    Barany, Peter
    Heimburger, Olof
    Lindholm, Bengt
    Stenvinkel, Peter
    [J]. PLOS ONE, 2018, 13 (01):
  • [2] Inflammation and Progression of CKD: The CRIC Study
    Amdur, Richard L.
    Feldman, Harold I.
    Gupta, Jayanta
    Yang, Wei
    Kanetsky, Peter
    Shlipak, Michael
    Rahman, Mahboob
    Lash, James P.
    Townsend, Raymond R.
    Ojo, Akinlolu
    Roy-Chaudhury, Akshay
    Go, Alan S.
    Joffe, Marshall
    He, Jiang
    Balakrishnan, Vaidyanathapuram S.
    Kimmel, Paul L.
    Kusek, John W.
    Raj, Dominic S.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 11 (09): : 1546 - 1556
  • [3] The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease
    Anders, Hans-Joachim
    Andersen, Kirstin
    Stecher, Baerbel
    [J]. KIDNEY INTERNATIONAL, 2013, 83 (06) : 1010 - 1016
  • [4] Comparison of hemodialysis with medium cut-off dialyzer and on-line hemodiafiltration on the removal of small and middle-sized molecules
    Belmouaz, Mohamed
    Diolez, Jeremy
    Bauwens, Marc
    Duthe, Fabien
    Ecotiere, Laure
    Desport, Estelle
    Bridoux, Frank
    [J]. CLINICAL NEPHROLOGY, 2018, 89 (01) : 50 - 56
  • [5] Impact of Cholecalciferol Treatment on Biomarkers of Inflammation and Myocardial Structure in Hemodialysis Patients Without Hyperparathyroidism
    Bucharles, Sergio
    Barberato, Silvio Henrique
    Stinghen, Andrea E. M.
    Gruber, Betina
    Piekala, Luciana
    Dambiski, Claudia
    Custodio, Melani R.
    Pecoits-Filho, Roberto
    [J]. JOURNAL OF RENAL NUTRITION, 2012, 22 (02) : 284 - 291
  • [6] Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients
    Caglar, Kayser
    Yilmaz, Mahmut Ilker
    Saglam, Mutlu
    Cakir, Erdinc
    Acikel, Cengizhan
    Eyileten, Tayfun
    Yenicesu, Mujdat
    Oguz, Yusuf
    Vural, Abdulgaffar
    Carrero, Juan Jesus
    Axelsson, Jonas
    Lindholm, Bengt
    Stenvinkel, Peter
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (01): : 61 - 68
  • [7] Inflammation in End-Stage Renal Disease-What Have We Learned in 10 Years?
    Carrero, Juan J.
    Stenvinkel, Peter
    [J]. SEMINARS IN DIALYSIS, 2010, 23 (05) : 498 - 509
  • [8] Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son"
    Castillo-Rodriguez, Esmeralda
    Pizarro-Sanchez, Soledad
    Sanz, Ana B.
    Ramos, Adrian M.
    Dolores Sanchez-Nino, Maria
    Martin-Cleary, Catalina
    Fernandez-Fernandez, Beatriz
    Ortiz, Alberto
    [J]. TOXINS, 2017, 9 (04)
  • [9] Serum β-2 microglobulin levels predict mortality in dialysis patients:: Results of the HEMO study
    Cheung, Alfred K.
    Rocco, Michael V.
    Yan, Guofen
    Leypoldt, John K.
    Levin, Nathan W.
    Greene, Tom
    Agodoa, Lawrence
    Bailey, James
    Beck, Gerald J.
    Clark, William
    Levey, Andrew S.
    Ornt, Daniel B.
    Schulman, Gerald
    Schwab, Steven
    Teehan, Brendan
    Eknoyan, Garabed
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (02): : 546 - 555
  • [10] Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study
    Chin, Melanie P.
    Bakris, George L.
    Block, Geoffrey A.
    Chertow, Glenn M.
    Goldsberry, Angie
    Inker, Lesley A.
    Heerspink, Hiddo J. L.
    O'Grady, Megan
    Pergola, Pablo E.
    Wanner, Christoph
    Warnock, David G.
    Meyer, Colin J.
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2018, 47 (01) : 40 - 47